Prevention of thromboembolic complications in replacement arthroplasty with use of enoxiparin

Abstract

Replacement arthroplasty is connected with a high risk of complications, deep vein thrombosis and pulmonary embolism being the most dangerous of them. Today low molecular weight heparins are regarded as the «gold standard» for preventing venous thromboembolic complications in case of orthopaedic interventions. The purpose of the present work was as follows: to study the effect of enoxiparin on the haemostasis system and assess its possible use in patients after total hip joint arthroplasty. Indices of clinical and biochemical analyses of blood and urine and coagulogrammes were estimated. The drug did not produce any negative effect on the indices of clinical and biochemical analyses of blood and urine. A higher content of the intravascular thrombopoiesis marker – reaction of the fibrin-monomer complex, fibrinolytic activity, D-dimer – was revealed. Anti-factor Xa activity was at the level, recommended for high risk patients. Hence, enoxiparin at a dose of 40 mg subcutaneously once a day improves indices of the haemostasis system during the postoperative period, does not cause any side or adverse effects and can be recommended for preventing thromboembolic complications in patients after hip joint arthroplasty.